BioGenCell

BioGenCell Overview

BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's technology creates autologous cells, derived from the patients themselves, to repair themselves. BioGenCell's lead product, BC1, uses the company's technology to treat blood vessel insufficiency, which can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, BioGenCell's easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. BioGenCell's patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (biobanking) of therapeutic cellular products for use in patient treatment.

Cumulative Funding Raised Over Time ($)

Latest News

Dec 19, 2024 · www.prnewswire.com

growth-positive

/PRNewswire/ -- BioGenCell, a biotechnology leader in regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

BioGenCell, a leader in regenerative medicine, has been granted Fast Track Designation by the FDA for its lead candidate, BGC101, aimed at treating severe Critical Limb Threatening Ischemia (CLTI). This designation allows for accelerated clinical development and compassionate-use access for eligible patients. BGC101 uses BioGenCells proprietary TRACT platform to create personalized cell therapies from a patients own blood, promoting tissue regeneration and restoring blood flow. The company has completed patient recruitment for its Phase 2 clinical trial, which focuses on amputation-free survival and symptom relief. This milestone highlights the potential of BioGenCells innovative approach to address unmet medical needs in CLTI.

Jul 11, 2024 · www.calcalistech.com

growth-positive

BioGenCell pioneers revolutionary cell therapy for microvascular disease | CTech

BioGenCell, an Israeli biotech company, is developing a cell therapy treatment for microvascular diseases, a common and debilitating illness often resulting from advanced diabetes. The companys treatment combines immune and stem cell therapies to produce personalized cell treatments using the patients own blood. The treatment has shown promising results, with a 100% amputation-free survival rate in Phase 1 trials. The company, which has raised a total of $16 million, is currently raising funds for its Phase 3 trials and plans to expand its manufacturing capabilities globally.

InvestmentExpand

May 9, 2022 · www.calcalistech.com

growth-positive

BioGenCell raises $16 million Seed round led by Marius Nacht for microvascular diseases treatment CTech

Israeli biotechnology company BioGenCell has completed a $16 million Seed round led by private investor Marius Nacht. The company develops technology for using stem cells from the patient’s own blood to treat microvascular diseases. Their current product is intended for the treatment of chronic limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers. BioGenCell recently received FDA approval permission to continue to Phase II clinical trials.

Investment

May 25, 2020 · biogencell.net

Biogencell

May 24, 2020 · www.firstwordpharma.com

BioGenCell Ltd. appoints New Chair and Strengthens Board of Directors

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

Divrei Khayim Street 16, Netanya, Israel

Photos & Videos

1 item(s)

BioGenCell Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info